The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Final yr noticed a variety of therapy developments and information for sufferers with gastrointestinal cancers, together with gastrointestinal stromal tumors (GISTs), gallbladder...
CAR-T cell remedy brings outcomes that when appeared unimaginable: lengthy, remedy‑free remissions after a single infusion. For many individuals dwelling with relapsed...
